Laboratory Co. of America Holdings (NYSE:LH) Shares Acquired by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd raised its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 16.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,488 shares of the medical research company's stock after buying an additional 1,519 shares during the period. UniSuper Management Pty Ltd's holdings in Laboratory Co. of America were worth $2,405,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Graney & King LLC purchased a new position in Laboratory Co. of America in the 4th quarter worth about $26,000. Fortitude Family Office LLC increased its position in shares of Laboratory Co. of America by 312.5% during the fourth quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company's stock worth $30,000 after acquiring an additional 100 shares during the period. Geneos Wealth Management Inc. increased its position in shares of Laboratory Co. of America by 309.8% during the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company's stock worth $39,000 after acquiring an additional 127 shares during the period. Human Investing LLC bought a new stake in shares of Laboratory Co. of America during the fourth quarter valued at approximately $39,000. Finally, True Wealth Design LLC boosted its holdings in shares of Laboratory Co. of America by 3,660.0% in the third quarter. True Wealth Design LLC now owns 188 shares of the medical research company's stock valued at $42,000 after purchasing an additional 183 shares during the period. Institutional investors own 95.94% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

LH has been the subject of a number of research analyst reports. Redburn Atlantic began coverage on Laboratory Co. of America in a research report on Wednesday. They set a "buy" rating and a $276.00 target price for the company. Morgan Stanley lifted their price objective on Laboratory Co. of America from $260.00 to $270.00 and gave the company an "overweight" rating in a report on Tuesday, December 17th. Piper Sandler upped their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Bank of America raised their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Finally, StockNews.com lowered Laboratory Co. of America from a "buy" rating to a "hold" rating in a research report on Saturday, March 29th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $270.38.

Laboratory Co. of America Stock Performance

Shares of NYSE LH traded down $3.43 during mid-day trading on Thursday, hitting $232.94. The stock had a trading volume of 195,645 shares, compared to its average volume of 621,339. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. The company has a 50 day moving average of $244.33 and a two-hundred day moving average of $234.88. The firm has a market cap of $19.50 billion, a PE ratio of 26.41, a PEG ratio of 1.71 and a beta of 1.12. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $258.59.

Laboratory Co. of America (NYSE:LH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Research analysts predict that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.24%. The ex-dividend date of this dividend was Thursday, February 27th. Laboratory Co. of America's dividend payout ratio (DPR) is 32.65%.

Insider Activity at Laboratory Co. of America

In other news, COO Mark S. Schroeder sold 5,339 shares of the business's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $249.23, for a total value of $1,330,638.97. Following the completion of the sale, the chief operating officer now directly owns 4,960 shares in the company, valued at $1,236,180.80. The trade was a 51.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Amy B. Summy sold 758 shares of the company's stock in a transaction that occurred on Friday, March 28th. The stock was sold at an average price of $231.67, for a total value of $175,605.86. Following the transaction, the executive vice president now directly owns 5,302 shares of the company's stock, valued at approximately $1,228,314.34. The trade was a 12.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,258 shares of company stock worth $3,753,177. 0.85% of the stock is owned by company insiders.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.